2020
Exposing Hidden Targets: Combining epigenetic and immunotherapy to overcome cancer resistance
Olino K, Park T, Ahuja N. Exposing Hidden Targets: Combining epigenetic and immunotherapy to overcome cancer resistance. Seminars In Cancer Biology 2020, 65: 114-122. PMID: 31911188, DOI: 10.1016/j.semcancer.2020.01.001.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsResponse ratePeripheral T-cell lymphomaTriple-negative breast cancerLarge B-cell lymphomaDurable response rateEffective standard therapyDeath protein 1Solid organ tumorsInhibitory immune receptorsT-cell lymphomaNegative breast cancerB-cell lymphomaAdvanced malignanciesMost patientsStandard therapyClinical efficacyCommon malignancyHepatobiliary cancersTherapeutic optionsNeck cancerOrgan tumorsInitial respondersOvarian cancerProstate cancerBreast cancer
2016
Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma
Thompson ED, Zahurak M, Murphy A, Cornish T, Cuka N, Abdelfatah E, Yang S, Duncan M, Ahuja N, Taube JM, Anders RA, Kelly RJ. Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma. Gut 2016, 66: 794. PMID: 26801886, PMCID: PMC4958028, DOI: 10.1136/gutjnl-2015-310839.Peer-Reviewed Original ResearchConceptsPD-L1 expressionProgression-free survivalEpstein-Barr virusT-cell densityImmune stromaOverall survivalPD-L1T cellsAdaptive immune resistance mechanismHigh PD-L1 expressionMembranous PD-L1 expressionStromal PD-L1 expressionCD8 T cell infiltrationWorse progression-free survivalImmune resistance mechanismsImmune checkpoint inhibitorsPD-L1 positivityPD-L1 statusGastro-oesophageal junctionImmune-based therapiesT cell infiltrationPercentage of tumorsTumor-stromal interfaceCD8 densityCD8 infiltration